Table 1.

Participant demographics and randomization factors.

	QGTC n=21)	LE n=21)	WLC n=24)	p
Age (years: mean, SD)	62.2 (7.4)	65.0 (5.9)	66.0 (8.4)	0.212
Race				0.392
White	20 (95.2)	18 (85.7)	23 (95.8)
Hispanic	1 (4.8)	2 (9.5)	-
Black	-	-	1 (4.2)
Asian	-	1 (4.8)	-
Marital status (n=63)				0.714
Co-habitating (married, living with a partner)	15 (71.4)	19 (90.5)	20 (83.3)
Not cohabitating (not married, divorced, separated)	5 (29.6)	1 (9.5)	3 (16.7)
Education (n=65)				0.709
High school or technical school	5 (23.8)	3 (14.3)	2 (8.7)
Some college	4 (19.0)	4 (19.0)	4 (17.4)
Higher education	12 (57.2)	14 (66.7)	17 (73.9)
Time since diagnosis [months: mean (SD); n=65]	8.0 (7.9)	20.8 (32.4)	27.7 (53.2)	0.211
Stage				0.972
T1–T2a	10 (47.6)	10 (47.6)	13 (54.2)
T2b-T2c	6 (28.6)	7 (33.3)	6 (25.0)
T3a and above	5 (23.8)	4 (19.1)	5 (20.8)
Gleason score (n=65)				0.996
≤6	2 (10.0)	2 (9.5)	2 (8.3)
7	13 (65.0)	14 (66.7)	16 (66.7)
8–9	5 (25.0)	5 (23.8)	6 (25.0)
PSA level (n=65)				0.879
≤10	17 (81.0)	17 (81.0)	19 (82.6)
10.1–20	3 (14.3)	3 (14.3)	4 (17.4)
>20	1 (4.7)	1 (4.7)	-
XRT timing				0.602
Definitive	14 (66.7)	14 (66.7)	13 (54.2)
Adjuvant	7 (33.3)	7 (33.3)	11 (46.8)
Type of radiation received				0.750
IMRT	8 (38.1)	10 (47.6)	9 (37.5)
Proton	13 (61.9)	11 (52.4)	15 (62.5)
Baseline anxiety levels (mean, SD)	35.0 (11.1)	32.6 (9.7)	32.5 (11.7)	0.698
Concurrent androgen deprivation therapy				0.934
Yes	16 (76.2)	15 (71.4)	18 (75.0)
No	5 (23.8)	6 (29.6)	6 (25.0)

QGTC: Qigong/tai chi treatment group; LE: Light exercise; WLC: Waitlist control; PSA: Prostate-Specfic Antigen; XRT: radiation therapy; IMRT: Intensity-Modulated Radiation Therapy